Cargando…
Non-capsulated Neisseria meningitidis sepsis in a paroxysmal nocturnal hemoglobinuria patient treated with ravulizumab: case report and review of the literature
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired haematopoietic stem cell disease characterized by complement-mediated intravascular hemolysis, thrombosis, and bone marrow failure. Eculizumab and ravulizumab are anti-C5 monoclonal antibodies that reduce hemolysis, anaemia and thrombotic...
Autores principales: | Galli, Nicole, Pettine, Loredana, Panigada, Mauro, Daprai, Laura, Suriano, Grazia, Grancini, Anna, Barcellini, Wilma, Fattizzo, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580757/ https://www.ncbi.nlm.nih.gov/pubmed/37854608 http://dx.doi.org/10.3389/fimmu.2023.1269325 |
Ejemplares similares
-
Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties
por: Fattizzo, Bruno, et al.
Publicado: (2021) -
Managing Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria: A Patient-Focused Perspective
por: Fattizzo, Bruno, et al.
Publicado: (2022) -
Paroxysmal Nocturnal Hemoglobinuria in the Context of a Myeloproliferative Neoplasm: A Case Report and Review of the Literature
por: Giannotta, Juri Alessandro, et al.
Publicado: (2021) -
Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
por: Gurnari, Carmelo, et al.
Publicado: (2021) -
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria
por: Stern, Robert M., et al.
Publicado: (2019)